Tirzepatide Matches Competitor's Cardioprotective Benefits for Diabetics

(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) in patients with type 2 diabetes and atherosclerotic cardiovascular disease, a large…

Source link : https://www.medpagetoday.com/cardiology/prevention/119074

Author :

Publish date : 2025-12-17 22:47:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Tirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics

Two Extended-Release Buprenorphine Doses Effective in High-Risk Opioid Use Disorder

Related Posts

Two Extended-Release Buprenorphine Doses Effective in High-Risk Opioid Use Disorder

Major Developments in Psoriatic Disease

ADHD App Cleared; Anti-Inflammatories for Depression; Charges Over Adderall Scripts

Big Bump in Concierge, Direct Primary Care in Recent Years

Undesired Weight Gain Common in HIV Patients on ART

Improving Oral Chemotherapy Adherence in Pediatric ALL

Tirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics

Two Extended-Release Buprenorphine Doses Effective in High-Risk Opioid Use Disorder

Major Developments in Psoriatic Disease

ADHD App Cleared; Anti-Inflammatories for Depression; Charges Over Adderall Scripts

Big Bump in Concierge, Direct Primary Care in Recent Years

Undesired Weight Gain Common in HIV Patients on ART

Improving Oral Chemotherapy Adherence in Pediatric ALL

Can an AI-Based Tool Help Predict Cardiovascular Events?

Categories

Archives